Cite
MLA Citation
Izuma Nakayama et al.. “Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.” BMC cancer, vol. 17, no. 1, 2017, pp. 1–9. http://access.bl.uk/ark:/81055/vdc_100080997903.0x0001ad